BioNTech SE - ADR

BioNTech SE - ADR

BNTX

Market Cap$23.03B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
BioNTech SE - ADRBioNTech SE - ADR-26.4--4%10.1-

Earnings Call Q1 2025

May 5, 2025 - AI Summary

Financial Performance and Guidance: BioNTech reported total revenues of approximately €183 million in Q1 2025, slightly down from €188 million in Q1 2024, reflecting the seasonality expected in an endemic COVID-19 environment. The company maintains a revenue guidance of €1.7 billion to €2.2 billion for the fiscal year 2025, projecting steady vaccination rates and pricing, while R&D expenses are expected in the range of €2.6 billion to €2.8 billion.
Net Loss and Cash Position: The company reported a net loss of €416 million for Q1 2025, increasing from a loss of €315 million YOY, translating to a basic and diluted loss per share of €1.73. Despite the losses, BioNTech ended the quarter with a strong cash position of €15.9 billion, indicating sufficient liquidity to fund ongoing and future projects.
Oncology Pipeline Progress: BioNTech is advancing its oncology programs, particularly BNT327 (a bispecific antibody) and BNT323 (HER2 ADC), both positioned for BLA submissions aimed for potential accelerated approval. Key trials are being conducted for indications such as triple-negative breast cancer and small cell lung cancer, reflecting the company's strategy to target high unmet medical needs, with an emphasis on combination therapies.

Exclusive for Stockcircle Pro members

Sign upSign Up
$129.67

Target Price by Analysts

16.7% upsideBioNTech SE Target Price DetailsTarget Price
$82.57

Current Fair Value

25.7% downside

Overvalued by 25.7% based on the discounted cash flow analysis.

Share Statistics

Market cap$23.03 Billion
Enterprise Value$13.44 Billion
Dividend Yield$0 (0%)
Earnings per Share$-2.77
Beta1.36
Outstanding Shares240,346,821

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio-26.42
PEG-82.68
Price to Sales10.1
Price to Book Ratio1.42
Enterprise Value to Revenue4.89
Enterprise Value to EBIT-20.71
Enterprise Value to Net Income-18
Total Debt to Enterprise0.04
Debt to Equity0.03

Revenue Sources

No data

Insider Trades

ESG Score

No data

About BioNTech SE